La Vecchia Carlo, Rota Matteo, Malvezzi Matteo, Negri Eva
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; Department of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri," Milan, Italy
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; Department of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri," Milan, Italy.
Oncologist. 2015 May;20(5):495-8. doi: 10.1634/theoncologist.2015-0011. Epub 2015 Apr 17.
Overall age-standardized cancer mortality rates in the European Union (EU) have declined by approximately 20% through 2010 (17% in women, 22% in men) since the peak value reached in 1988. This corresponds to the avoidance of more than 250,000 cancer deaths in 2010 alone and approximately 2.2 million deaths over the 1989-2010 22-year period. A more than twofold difference remains between the highest cancer mortality rates (in Hungary and other central European countries) and the lowest (in selected Nordic countries and Switzerland). Part of this gap is due to tobacco, alcohol, and other lifestyle and environmental exposures, and another part is attributable to differences in cancer diagnosis, treatment, and management. There are also appreciable differences in 5-year cancer survival across the EU, with lower survival rates in central and eastern Europe. If overall cancer survival in EU countries with low rates could be raised to the median, approximately 50,000 additional cancer deaths would be avoided per year, and more than 100,000 would be avoided if overall survival in all countries were at least that of the 75% percentile--4% and 8%, respectively, of the approximately 1.3 million cancer deaths registered in the EU in 2010. There is, however, substantial uncertainty about any such estimate because differences in cancer survival are partly or largely attributable to earlier diagnosis, in variable proportion for each cancer site and probably to different degrees in different countries, even in the absence of changes in the date of death or avoidance of death. Consequently, these approximations are the best available and may be used cautiously to compare countries, health care approaches, and changes that occur over time.
自1988年达到峰值以来,截至2010年,欧盟(EU)总体年龄标准化癌症死亡率下降了约20%(女性为17%,男性为22%)。这意味着仅在2010年就避免了超过25万例癌症死亡,在1989 - 2010年的22年期间避免了约220万例死亡。癌症死亡率最高的国家(匈牙利和其他中欧国家)与最低的国家(部分北欧国家和瑞士)之间仍存在两倍多的差距。造成这种差距的部分原因是烟草、酒精以及其他生活方式和环境暴露因素,另一部分原因则是癌症诊断、治疗和管理方面的差异。欧盟各国的癌症5年生存率也存在显著差异,中东欧地区的生存率较低。如果癌症生存率较低的欧盟国家能够将总体生存率提高到中位数水平,那么每年大约可避免5万例额外的癌症死亡;如果所有国家的总体生存率至少达到第75百分位数,那么每年可避免超过10万例死亡,这分别占2010年欧盟登记的约130万例癌症死亡病例的4%和8%。然而,任何此类估计都存在很大的不确定性,因为癌症生存率的差异部分或很大程度上归因于更早的诊断,不同癌症部位的比例各不相同,而且在不同国家可能程度也不同,即使死亡日期没有变化或避免了死亡。因此,这些近似值是目前可得的最佳数据,可以谨慎地用于比较不同国家、医疗保健方法以及随时间发生的变化。